Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT)

Anti-Cancer Drug Design

Volumn 14, Issue 6, 1999, Pages 517-538

  Niculescu Duvaz, Ion ^a   Friedlos, Frank ^a   Niculescu Duvaz, Dan ^a   Davies, Lawrence ^a   Springer, Caroline J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

ADEPT; Bystander effect; Enzyme; GDEPT; Gene therapy; Prodrug; Viral vectors

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ALKYLATING AGENT; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CARBOXYPEPTIDASE G2; CHLORMETHINE; ENZYME; NITROREDUCTASE; PRODRUG; TUMOR ANTIGEN;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ARTICLE; CANCER; CLINICAL TRIAL; DRUG ACTIVATION; DRUG DESIGN; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TARGETING; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; GENE THERAPY; HUMAN; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; TUMOR CELL;

ANIMALS; ANTIBODIES, NEOPLASM; DRUG DESIGN; GENE THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PRODRUGS;

EID: 0033502650     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (94)

1. Andrianomenjanahary S., Dong X., Florent J.C., Gaudel G., Gesson J.P., Jacquesy J.C., Koch M., Michel S., Mondon M., Monneret C., Petit P., Renoux B., Tillequin F. (1992) Synthesis of novel targeted pro-drugs of anthracyclines potentially activated by a monoclonal antibody galactosidase conjugate (Part 1). Bioorganic Medicinal Chemical Letters, 2, 1093.
2. Anlezark G. M., Melton R.G., Sherwood R.F., Coles B., Friedlos F., Knox R.J. (1992) The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954). 1. Purification and properties of nitroreductase enzyme from E. coli, a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochemical Pharmacology, 44, 2289.
3. Anlezark G.M., Melton R.G., Sherwood R.F., Wilson W.R., Denny W.A., Palmer B.D., Knox R.J., Friedlos F., Williams A. (1995) Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase. Biochemical Pharmacology, 50, 609.
4. Antoniw P., Springer C.J., Bagshawe K.D., Searle F., Melton R.G., Rogers G.T., Burke P.J., Sherwood R.F. (1990) Disposition of the prodrug 4-[bis(2-chloroethyl)amino]-benzoyl-L-glutamic acid and its active parent drug in mice. British Journal of Cancer, 62, 909.
5. Azoulay M., Florent J.C., Monneret C., Gesson G.P., Jaquesy G.P., Tillequin F., Koch M., Bosslet K., Czech J., Hoffman D. (1995) Prodrugs of anthracycline antibiotics suited for tumor-specific activation. Anti-Cancer Drug Design, 10, 441.
6. Bagshawe K.D. (1989) Toward generating cytotoxic agents at cancer sites. British Journal of Cancer, 60, 275.
7. Bagshawe K.D., Springer C.J., Searle F., Antoniw P., Sharma S.K., Melton R.G., Sherwood R.F. (1988) A cytotoxic agent can be generated selectively at cancer sites. British Journal of Cancer, 58, 700.
8. Bagshawe K.D., Sharma S.K., Springer C.J., Antoniw P., Boden J.A., Rogers G.T., Burke P.J., Melton R.G., Sherwood R.F. (1991) Antibody-Directed Enzyme Prodrug Therapy (ADEPT): clinical report. Disease Markers, 9, 233.
9. Bagshawe K.D., Sharma S.K., Springer C.J., Rogers G.T. (1994) Antibody-Directed Enzyme Prodrug Therapy (ADEPT): a review of some theoretical, experimental and clinical aspects. Analytical Oncology, 5, 879.
10. Bailey S.M., Knox R.J., Hobbs S.M., Jenkins T.C., Mauger A.B., Melton R.G., Burke P.J., Connors T.A., Hart I.R. (1996) Investigation of alternative prodrugs for use with E. coli nitroreductase in suicide gene approaches to cancer therapy. Gene Therapy, 3, 1143.
11. Bakina E., Zheng W., Rosenblum M., Farquhar D. (1997) Intensely cytotoxic anthracycline prodrugs: glucuronides. Journal of Medicinal Chemistry, 40, 4013.
12. Blakey D.C., Burke P.J., Davies D.H., Dowell R., East S.J., Ekersley K.P., Fitton J.E., McDaid J., Melton R.G., Niculescu-Duvaz I., Pinder P.E., Sharma S.K., Wright A.F., Springer C.J. (1996) ZD 2767, an improved system for antibody-directed prodrug therapy that results in tumor regressions in colorectal tumor xenografts. Cancer Research, 56, 3287.
13. Boland M.P., Knox R.J., Roberts J.J. (1991) The differences in kinetics of rat and human DT-diaphorase result in a differential sensitivity of cells lines to CB 1954 [5-(aziridin-1-yl)-2,4-dinitrobenzamide. Biochemical Pharmacology, 41, 867.
14. Bosslet K., Czech J., Hoffmann D. (1994) Tumor-selective prodrug activation by fusion protein-mediated catalysis. Cancer Research, 54, 2151.
15. Bridgewater G., Springer C.J., Knox R., Minton N., Michael P., Collins M. (1995) Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB 1954. European Journal of Cancer, 31A, 2362.
16. Cambanis A., Dobre V., Niculescu-Duvaz I. (1969) Potential anticancer agents. 5. Nitrogen mustards related to 3[N,N-bis(2-chloroethyl)amino]-4-methyl benzoic acid. Journal of Medicinal Chemistry, 12, 161.
17. Carl P.L., Chakravarty P.K., Katzenellenbogen J.A. (1981) A novel connector linkage applicable in prodrug design. Journal of Medicinal Chemistry, 24, 479.
18. Cobb L.M., Connors T.A., Elson L.A., Khan A.H., Mitschley B.V.C., Ross W.C.J., Whisson M.E. (1969) 2,4-Dinitro-5-ethyleneiminobenzamide (CB 1954): a potent and selective inhibitor of growth of the Walker carcinoma 256. Biochemical Pharmacology, 18, 1519-1527.
19. Denny W.A., Wilson W.R. (1998) The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies. Journal of Pharmaceutical Pharmacology, 50, 387.
20. Deonarain M.P., Epenetos A.A. (1994) Targeting enzymes for cancer therapy: old enzymes in new roles. British Journal of Cancer, 70, 786.
21. Deziel R. (1987) Mild palladium(0)-catalyzed deprotection of allylesters. An useful application in the synthesis of carbapenem and other β-lactam derivatives. Tetrahedron Letters, 28, 4371.
22. Dowell R., Springer C.J., Davies D.H., Hadley E.M., Burke P.J., Boyle F.T., Melton R.G., Connors T.A., Blakey D.C., Mauger A.B. (1996) New mustards prodrugs for antibody-directed enzyme prodrug therapy: alternative for the amide link. Journal of Medicinal Chemistry, 39, 1100.
23. Du Frain R.J., Littlefield L.G., Wilmer J.L. (1979) Cyclophosphamide induced SCEs in rabbit lymphocites. Environmental Mutagenesis, 1, 283.
24. Encell L.P., Loeb L.A. (1998) Improving enzymes for cancer gene therapy. Tumor Targeting, 3, 191.
25. Farquhar D., Cherif A., Bakina E., Nelson J.A. (1998 Intensely potent doxorubicin analogues: structure - activity relationship. Journal of Medicinal Chemistry, 41, 965.
26. Friedlos F., Knox R.J. (1992) Metabolism of NAD(P)H by blood components. Relevance to bioreductively activated prodrugs in a targeted enzyme therapy system. Biochemical Pharmacology, 44, 631.
27. Friedlos F., Jarman M., Davies L.C., Boland M.P., Knox R.J. (1992a) Identification of novel reduced pyridinium derivatives as synthetic cofactors for the enzyme DT diaphorase NAD(P)H dehydrogenase (quinone), EC 1.6.99.2. Biochemical Pharmacology, 44, 25.
28. Friedlos F., Biggs P.J., Abrahamson J.A., Knox R.J. (1992b) Potentiation of CB 1954 cytotoxicity by reduced pyrimidine nucleotides in human tumour cells by stimulation of DT diaphorase activity. Biochemical Pharmacology, 44, 1739.
29. Friedlos F., Denny W.A., Palmer B.D., Springer C.J.S. (1997) Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy. Journal of Medicinal Chemistry, 40, 1270.
30. Friedlos F., Court S., Ford M., Denny W.A., Springer C.J. (1998) Gene-directed enzyme prodrug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cell expressing bacterial nitroreductase. Gene Therapy, IB, 105.
31. Gesson J.P., Jacquesy J.C., Mondon M., Petit P., Renoux B., Andrianomenjanahary S., Van Dufat-Trinh H., Koch M., Michel S., Tillequin F., Florent J.C., Monneret C., Bosslet K., Czech J., Hoffmann D. (1994) Prodrugs of anthracyclines for chemotherapy via enzyme - monoclonal antibody conjugates. Anti-Cancer Drug Design, 9, 409.
32. Green N.K., Youngs D.J., Neoptolemos J.P., Friedlos F., Knox R., Springer C.J., Anlezark G.M., Michael N.P., Melton R.G., Ford M.J., Young L.S., Kerr D.J., Searle P.F. (1997) Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Therapy, 4, 228.
33. Grever R., Chabner B.A. (1997) Cancer Drug Discovery and Development, Vol. 1, 5th edn. Lippincot-Raven: New York.
34. Gupta S.P. (1994) Quantitative structure - activity relationships studies on anticancer agents. Chemical Reviews, 94, 1507.
35. Haisma H.J., Boven E., van Muijen M., de Jong J., van der Vygh W.J.F., Pinedo H.M. (1992) A monoclonal antibody-β-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for the specific treatment of cancer. British Journal of Cancer, 66, 474.
36. Haisma H.J., Van Muijen M., Pinedo H.M., Boven E. (1994) Comparison of two anthracycline-based produgs for activation by a monoclonal antibody-β-glucuronidase conjugate in specific treatment of cancer. Cell Biophysics, 24/25, 185.
37. Hansch C., Leo A., Hoekman D. (1995) Exploring QSAR. Hydrophobic, Electronic and Steric Constants. American Chemical Society: Washington, DC.
38. Hay M.P., Denny W.A. (1996) Antibody-directed enzyme-prodrug therapy (ADEPT). Drugs of the Future, 21, 917.
39. Honda M., Morita H., Nagakura I. (1997) Deprotection of allyl groups with sulfinic acids and palladium catalyst. Journal of Organic Chemistry, 62, 8932.
40. Huber B.E., Richards C.A., Austin E.A. (1995) VDEPT. An enzyme/prodrug gene therapy approach for the treatment of metastatic colorectal cancer. Advanced Drug Delivery Reviews, 17, 279.
41. Jarman M., Bisset G.M.F., Thornton J.T. (1993) Synthesis of tetrafluorinated analogue of the quinazolin antifolate 2-desamino-2-methyl-N(10)-propargyl-5,8-dideazafolic acid. Journal of Fluorine Chemistry, 60, 31.
42. Jungheim L.N., Shepherd T.A., Kling J.K. (1993) Synthesis of a cephalosporin - doxorubicin antitumor prodrug: a substrate for an antibody-targeted enzyme. Heterocycles, 35, 339.
43. Jungheim L.N., Shepherd T.T. (1994) Design of antitumor prodrugs: substrates for antibody targeted enzymes. Chemical Reviews, 94, 1553.
44. Knox R.J., Boland M.P., Friedlos F., Coles B., Southan C., Roberts J.J. (1988) The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). Biochemical Pharmacology, 44, 2297.
45. Knox R.J., Friedlos F., Marchbank T., Roberts J.J. (1991) Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA - DNA interstrand crosslinking species. Biochemical Pharmacology, 42, 1691.
46. Knox R.J., Friedlos F., Sherwood R.F., Melton R.G., Anlezark G.M. (1992) The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954). II. A comparison of an Escherichia coli nitroreductase and Walker DT-diaphorase. Biochemical Pharmacology, 44, 2297.
47. Knox R.J., Friedlos F., Jarman M., Davies L.C., Goddard P., Anlezark G.M., Melton R.G., Sherwood R.F. (1995) Virtual cofactors for an E. coli nitroreductase enzyme: relevance to reductively activated prodrugs in antibody-directed enzyme prodrug therapy (ADEPT). Biochemical Pharmacology, 49, 1641.
48. Madec-Lougerstay R., Florent J.C., Monneret C. (1999) Synthesis of self-immolative glucuronide spacers based on aminomethylcarbamates. Application to 5-fluorouracil prodrugs for antibody-directed enzyme prodrug therapy. Journal of Chemical Society, Perkin Transactions 1, 1369.
49. Marais R., Spooner R.A., Light Y., Martin J., Springer C.J. (1996) Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Research, 56, 4735.
50. Marais R., Spooner R.A., Stribbling S.M., Light S.M., Martin J., Springer C.J. (1997) A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy. Nature Biotechnology, 15, 1373.
51. Matthews B.W. (1988) Structural basis of the action of thermolysin and related zinc peptidases. Accounts of Chemical Research, 21, 333.
52. Melton R.G., Searle F., Sherwood R.F., Bagshawe K.D., Boden J.A. (1990) The potential of carboxypeptidase G2: antibody conjugates as anti-tumor agents. 2. In vivo localising and clearance properties in a choriocarcinoma model. British Journal of Cancer, 61, 420.
53. Melton R.G., Sherwood R.F. (1996) Antibody - enzyme conjugates for cancer therapy. Journal of the National Cancer Institute, 88, 153.
54. Minton N.P., Atkinson T., Bruton C.J., Sherwood R.F. (1984) The complete nucleotide sequence of the Pseudomonas gene coding for carboxypeptidase G2. Gene, 31, 31.
55. Napier M.P., Sharma S.K., Springer C.J., Bagshawe K.D., Green A.J., Martin J., Stribbling S.M., Cushen N., O'Malley D., Begent R.H.J. (1999) Antibody-directed enzyme prodrug therapy (ADEPT): efficacy and mechanism of action in colorectal carcinoma. Clinical Cancer Research, in press.
56. Niculescu-Duvaz I., Springer C.J. (1994) Adamantanyloxycarbonyl: a novel protecting group for phenols carrying strongly electron-withdrawing substituents. Journal of Chemical Research, 242.
57. Niculescu-Duvaz I., Springer C.J. (1995) Antibody-directed enzyme prodrug therapy (ADEPT): a targeting strategy in chemotherapy. Current Medicinal Chemistry, 2, 687.
58. Niculescu-Duvaz I., Springer C.J. (1996) Development of prodrugs for ADEPT (antibody-directed prodrug therapy). Expert Opinion on Investigational Drugs, 3, 289.
59. Niculescu-Duvaz I., Springer C.J. (1997) Gene-directed enzyme prodrug therapy: a review of enzyme/prodrug combinations. Expert Opinion on Investigational Drugs, 6, 685.
60. Niculescu-Duvaz I., Craescu T., Stihi G., Simon G. (1980) Potential anticancer agents. 20. Quantitative structure -activity relationships (QSAR) in the field of nitrogen mustards. Neoplasma, 27, 271.
61. Niculescu-Duvaz I., Spooner R.A., Marais R., Springer C.J.S. (1998a) Gene-directed enzyme prodrug therapy. Bioconjugate Chemistry, 9, 4.
62. Niculescu-Duvaz D., Niculescu-Duvaz I., Friedlos F.F., Martin J., Spooner R., Davies, L., Marais R., Springer C.J. (1998b) Self-immolative mustard prodrugs for suicide gene therapy. Journal of Medicinal Chemistry, 41, 5297.
63. Niculescu-Duvaz I., Cooper R.G., Stribbling S.M., Heyes J.A., Metcalfe J.A., Springer C.J. (1999a) Recents developments in gene-directed enzyme prodrug therapy (GDEPT) for cancer. Current Opinion in Molecular Therapeutics, 1, 480.
64. Niculescu-Duvaz I., Niculescu-Duvaz D., Friedlos F., Spooner R., Martin J., Marais R., Springer C.J. (1999b) Self-immolative anthracycline prodrugs for suicide gene therapy. Journal of Medicinal Chemistry, 42, 2485.
65. Nishihara E., Nagayama Y., Narimatsu M., Namba H., Watanabe M., Niwa M., Yamashita S. (1998) Treatment of thyroid carcinoma cells with four different suicide gene/prodrug combinations in vitro. Anticancer Research, 18, 1521.
66. Palmer B.D., Wilson W.R., Atwell G.J., Schultz D., Xu X.D., Denny W.A. (1994) Hypoxia selective antitumor agents. 9. Structure - activity relationships for hypoxia-selective cytotoxicity of 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide. Journal of Medicinal Chemistry, 37, 2175.
67. Panthananical A., Hansch C., Leo A., Quinn F.R. (1978) Structure - activity relationships in antitumor aniline mustards. Journal of Medicinal Chemistry, 21, 16.
68. Roberts J.J., Friedlos F., Knox R.J. (1986) CB 1954 (2,4-dinitro-5-aziridinyl benzamide) becomes a DNA interstrand crosslinking agent in Walker tumour cells. Biochemistry and Biophysics Research Communications, 140, 1073.
69. Rodrigues M.L., Presta L.G., Kotts C.E., Wirth C., Mordenti C., Osaka G., Wong W.T., Nuijens A., Blackburn B., Carter P. (1995) Development of a humanized disulfide-stabilized anti-p185HER Fv-β-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug. Cancer Research, 55, 63.
70. Rosowski A., Yu C.S. (1978) Methotrexate analogues. 10. Direct coupling of methotrexate and diethyl-L-glutamate in the presence of peptide bond-forming reagents. Journal of Medicinal Chemistry, 21, 170.
71. Rosowsky A., Forsh R., Uren J., Wick M. (1981) Methotrexate analogues. 14. Synthesis of new γ-substituted derivatives as dihydrofolate reductase inhibitors and potential anticancer agents. Journal of Medicinal Chemistry, 24, 1450.
72. Roswell S., Pauptit R.A., Tucker A.D., Melton R.G., Blow D.M., Brick P. (1997) Crystal structure of carboxypeptidase G2, a bacterial enzyme with applications in cancer therapy. Structure, 5.
73. Roth J.A., Cristiano R.J. (1997) Gene therapy for cancer: what have we done and where are we going? Journal of the National Cancer Institute, 89, 21.
74. Schmidt F., Florent J.-C., Monneret C., Straub R., Czech J., Gerken M., Bosslet K. (1997) Glucuronide prodrugs of hydroxy compounds for antibody directed enzyme prodrug therapy (ADEPT): a phenol nitrogen mustard carbamate. Bioorganic Medicinal Chemical Letters, 7, 1071.
75. Senter P.D., Wallace P.M., Svensson H.P., Vrudhula V.M., Kerr D.E., Hellström I., Hellström K.E. (1993) Generation of cytotoxic agents by targeted enzymes. Bioconjugate Chemistry, 4, 3.
76. Senter P.D., Svensson H.P., Schreiber G.J., Rodriguez G.L., Vrudhula V.M. (1995) Poly(ethylene glycol)-doxorubicin conjugates containing β-lactamase-sensitive linkers. Bioconjugate Chemistry, 6, 389.
77. Sharma S.K., Bagshawe K.D., Burke P.J., Boden J.A., Rogers G.T., Antoniw P., Springer C.J., Melton R.G., Sherwood R.F. (1994) Galactosylated antibodies and antibody -enzyme conjugates in ADEPT. Cancer, 73, 1114.
78. Sherwood R.F., Melton R.G., Alwan S.M., Hughes P. (1985) Purification and properties of carboxypeptidase G2 Pseudomonas sp strain RS-16. European Journal of Biochemistry, 148, 447.
79. Springer C.J., Niculescu-Duvaz I. (1995) Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs. Anti-Cancer Drug Design, 10, 361-372.
80. Springer C.J., Niculescu-Duvaz I. (1999) Patent property of prodrugs involving suicide gene therapy. Expert Opinion on Therapeutic Patents, 9, 1381.
81. Springer C.J., Antoniw P., Bagshawe K.D., Searle F., Bisset G.M.F., Jarman M. (1990) Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. Journal of Medicinal Chemistry, 33, 677.
82. Springer C.J., Antoniw P., Bagshawe K.D., Wilman D.E.V. (1991) Comparison of half-lives and cytotoxicity of N-mesyloxyethyl- and N-chloroethyl-4-amino benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT). Anti-Cancer Drug Design, 6, 467.
83. Springer C.J., Bagshawe K.D., Sharma S.K., Searle F., Boden J.A., Antoniw P., Burke P.J., Rogers G.T., Sherwood R.F., Melton R.G. (1991) Ablation of human choriocarcinoma xenografts in nude mice by Antibody-Directed Enzyme Prodrug Therapy (ADEPT) with three novel compounds. European Journal of Cancer, 27, 1361.
84. Springer C.J., Poon G. K., Sharma S.K., Bagshawe K.D. (1993) Identification of prodrug, active drug and metabonates in an ADEPT clinical study. Cell Biophysics, 22, 1.
85. Springer C.J., Niculescu-Duvaz I., Pedley R.B. (1994) Novel prodrugs of alkylating agents derived from 2-fluoro- and 3-fluoro benzoic acids for antibody-directed enzyme prodrug therapy. Journal of Medicinal Chemistry, 37, 2361.
86. Springer C.J., Niculescu-Duvaz I., Mauger A.B., Connors T.A., Burke P.J., Davies D.H., Dowell R.I., Boyle F.T., Blakey D.C., Melton R.G. (1995a) The design of prodrugs for Antibody Directed Enzyme Prodrug Therapy (ADEPT). In New Antibody Technologies and the Emergence of Useful Cancer Therapy, Begent R., Hamlin A. (eds), p. 75. The Royal Society of Medicine Press: London.
87. Springer C.J., Dowell R.L., Burke P.J., Hadley E., Davies D.H., Blakey D.C., Melton R.G., Niculescu-Duvaz I. (1995b) Optimization of alkylating prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for ADEPT. Journal of Medicinal Chemistry, 38, 5051.
88. Springer C.J., Niculescu-Duvaz I., East C.J., Dowell R.I., Davies D.M., Burke P.D., Melton R.G., Blakey D.C. (1995c) A new clinical candidate for Antibody-directed enzyme prodrug therapy (ADEPT), ZD 2767. Proceedings of the 8th AEK Symposium, Heidelberg.
89. Springer C.J., Bavetsias V., Jackman A.L., Boyle T.F., Marshall D., Pedley R.B., Bisset G.M.F. (1996) Prodrugs of thymidylate synthase inhibitors: potential for antibody directed enzyme prodrug therapy (ADEPT). Anti-Cancer Drug Design, 11, 625.
90. Teicher B.A., Frei E. III (1988) Development of alkylating agent resistant human tumor cell lines. Cancer Chemotherapy and Pharmacology, 21, 292.
91. Vrudhula N.H., Svensson H. P., Senter P.D. (1995) Cephalosporin derivatives of doxorubicin as prodrugs for activation by monoclonal antibody-β-lactamase conjugates. Journal of Medicinal Chemistry, 38, 1380.
92. Wakselman M. (1983) 1,4 and 1,6 eliminations from hydroxy- and amino-substituted benzyl systems: chemical and biochemical applications. Nouveau Journal de Chimie, 7, 439.
93. Wilman D.E.V., Boritzki T.J., Denny W.A. (1994) NMR and the determination of nitrogen mustards stability. British Journal of Cancer, 69 (Suppl. xxi), 56.
94. Zhang W.W., Fujiwara T., Grimm E.A., Roth J.A. (1995) Advances in cancer gene therapy. Advances in Pharmacology, 12, 289.